Polymorphism of FGD4 and myelosuppression in patients with esophageal squamous cell carcinoma

Chemotherapy-related adverse events may restrain taxane/cisplatin administration as a regimen for patients with esophageal squamous cell carcinoma. Genetic polymorphisms may contribute to adverse event susceptibility. The authors genotyped ten SNPs from five genes (rs1045642, rs2032582 and rs3213619 of ; rs2231137 and rs2231142 of ; rs246221 of ; rs3740066 of ; and rs10771973, rs12296975 and rs1239829 of ) in 219 patients with esophageal squamous cell carcinoma treated with taxane/cisplatin. Patients with severe toxicities were compared with those with minor or no adverse events by unconditional logistic regression models and semi-Bayesian shrinkage. After adjustment for age and sex, with the null prior, rs1239829 was statistically significantly related to grade 3-4 leukopenia (odds ratio [95% CI] in dominant model = 1.77 [1.04-3.03]). The minor allele of rs1239829 was related to grade 3-4 leukopenia in patients with esophageal squamous cell carcinoma treated with taxane/cisplatin, with unclear biological mechanism.